Horizon Competitors

Delisted . USA . 
Stock . Horizon Pharma PLC
HZNPDelisted Stock  USD 100.40  0.13  0.13%   
Horizon Pharma PLC competes with Bristol Myers, AbbVie, Merck, Gilead Sciences, and Johnson Johnson; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Horizon Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Horizon Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Horizon Pharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
100.40100.40100.40
Details
Intrinsic
Valuation
LowRealHigh
87.0287.02110.44
Details
Naive
Forecast
LowNextHigh
101.54101.54101.54
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
98.40101.55104.70
Details

Horizon Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Horizon Pharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Horizon and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Horizon Pharma PLC does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AZN
+ 0.94
LLY
NVS
+ 0.94
SNY
NVS
+ 0.93
JNJ
NVS
+ 0.93
AZN
SNY
+ 0.91
MRK
NVS
+ 0.91
LLY
  
High negative correlations   
SNY
- 0.95
BMY
NVS
- 0.9
BMY
AMGN
- 0.88
BMY
JNJ
- 0.88
BMY
MRK
- 0.88
BMY
AZN
- 0.86
BMY

Risk-Adjusted Indicators

There is a big difference between Horizon Stock performing well and Horizon Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Horizon Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BMY  1.30  0.33  0.13 (1.09) 1.20 
(1.49)
 2.23 
(2.07)
 14.39 
ABBV  1.01 (0.19) 0.00 (1.46) 0.00 
 0.00 
 2.30 
(2.39)
 18.93 
MRK  0.93 (0.24) 0.00 (0.80) 0.00 
 0.00 
 2.00 
(2.17)
 5.18 
GILD  1.00  0.23  0.09  1.33  1.14 
(0.99)
 2.17 
(1.82)
 10.80 
JNJ  0.60 (0.22) 0.00 (0.94) 0.00 
 0.00 
 1.40 
(1.55)
 3.25 
AMGN  1.08 (0.37) 0.00 (0.29) 0.00 
 0.00 
 1.85 
(4.16)
 9.43 
LLY  1.32 (0.22) 0.00 (0.47) 0.00 
 0.00 
 2.71 
(3.47)
 9.21 
AZN  1.06 (0.26) 0.00  1.75  0.00 
 0.00 
 1.32 
(2.78)
 8.50 
SNY  0.82 (0.30) 0.00 (6.63) 0.00 
 0.00 
 1.13 
(1.85)
 7.81 
NVS  0.68 (0.25) 0.00 (2.55) 0.00 
 0.00 
 1.12 
(1.52)
 6.05 
All Fundamental Data

Horizon Pharma Competitive Analysis

The better you understand Horizon Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Horizon Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Horizon Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HZNP BMY ABBV MRK GILD JNJ AMGN LLY AZN SNY
 0.13 
 100.40 
Horizon
 1.00 
 58.12 
Bristol
 0.74 
 174.37 
AbbVie
 0.86 
 100.61 
Merck
 1.93 
 92.34 
Gilead
 0.14 
 146.44 
Johnson
 0.85 
 273.41 
Amgen
 0.44 
 796.03 
Eli
 0.33 
 67.40 
AstraZeneca
 0.19 
 47.99 
Sanofi
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Good
Very Weak
Very Weak
OK
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Low
Low
Very Low
Very Low
Low
Low
Low
Very Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Sell
Hold
Buy
Strong Buy
Strong Buy
Strong Hold
Strong Hold
Cautious Hold
Hold
Current Ratio
3.96
1.42
0.93
1.46
1.43
1.43
1.68
1.13
0.81
1.3
Net Asset
9.11 B
95.16 B
134.71 B
106.67 B
62.12 B
167.56 B
97.15 B
64.01 B
101.12 B
126.46 B
Profit Margin
0.12
-0.15
0.0922
0.19
0.0045
0.17
0.13
0.2
0.13
0.093
EBITDA
1.11 B
19.37 B
17.31 B
6.91 B
7.61 B
29.34 B
7.9 B
8.57 B
13.42 B
12.6 B
Operating Margin
0.18
0.18
0.29
0.26
0.42
0.25
0.24
0.4
0.2
0.29
Current Valuation
26.87 B
161.18 B
375.82 B
275.87 B
131.11 B
368.51 B
198.35 B
746.68 B
238.13 B
139.52 B
Price To Book
5.1
6.88
51.46
5.67
6.11
5.03
19.53
50.5
5.12
1.57
Retained Earnings
590.01 M
28.77 B
(1000 M)
53.9 B
16.3 B
153.84 B
(26.55 B)
10.31 B
4.52 B
67.5 B
Current Asset
1.11 B
10.41 B
16.31 B
29.76 B
1.18 B
60.21 B
38.52 B
12.57 B
16.01 B
24.93 B
Five Year Return
N/A
2.96
4.33
2.99
3.76
2.59
2.82
1.83
2.99
3.85
Beta
1.01
0.44
0.61
0.41
0.19
0.52
0.6
0.43
0.18
0.45
Number Of Employees
2.19 K
34.1 K
50 K
70 K
18 K
131.9 K
26.7 K
43 K
89.9 K
86.09 K
Shares Outstanding
229 M
2.03 B
1.77 B
2.53 B
1.25 B
2.41 B
537.53 M
899.32 M
3.1 B
2.51 B
Cash Flow From Operations
1.26 B
13.86 B
22.84 B
13.01 B
8.01 B
22.79 B
8.47 B
4.24 B
10.35 B
10.26 B
Annual Yield
N/A
0.0413
0.0373
0.0325
0.0334
0.0338
0.0348
0.0075
0.0221
0.0424
Total Debt
2.56 B
41.46 B
59.38 B
36.27 B
24.99 B
29.33 B
64.61 B
25.23 B
28.62 B
18.42 B
Return On Equity
0.0854
-0.31
0.56
0.28
0.0056
0.21
0.56
0.65
0.17
0.0582
Z Score
7.48
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.0444
0.0607
0.0772
0.11
0.12
0.084
0.046
0.14
0.085
0.0416
Number Of Shares Shorted
7.1 M
25.6 M
19.32 M
32.79 M
23.41 M
18.54 M
11.14 M
5.84 M
7.4 M
4.53 M
Book Value Per Share
23.2
8.45
3.41
17.58
14.83
29.14
14.0
15.83
26.27
58.1
Current Liabilities
357.55 M
8.02 B
10.89 B
19.2 B
104.89 M
27.75 B
8.67 B
8.23 B
14.87 B
16.82 B
Total Asset
9.11 B
95.16 B
134.71 B
106.67 B
62.12 B
167.56 B
97.15 B
64.01 B
101.12 B
126.46 B
Debt To Equity
0.53
1.32
4.37
0.68
1.3
0.43
N/A
1.58
0.89
0.3
Short Ratio
2.04
2.16
2.46
2.7
3.21
2.47
2.89
1.05
0.92
2.0
Target Price
116.5
60.58
202.67
129.97
98.34
174.28
325.35
984.05
88.01
63.49
Last Dividend Paid
N/A
2.4
6.2
3.04
3.06
4.86
8.88
5.03
2.97
N/A
Shares Owned By Institutions
98.82
78.46
73.45
79.48
88.4
73.1
81.11
83.48
16.76
11.43
Market Capitalization
26.63 B
114.9 B
312.02 B
252.33 B
115.08 B
353.05 B
146.97 B
715.88 B
210.73 B
121.44 B
Price To Earning
32.55
24.88
21.28
18.05
359.42
24.69
22.74
54.92
103.39
7.78
Price To Earnings To Growth
1.0
2.0
0.42
0.0694
0.52
0.87
1.96
0.75
0.73
0.75
Price To Sales
6.93
2.42
5.62
3.99
4.07
4.03
4.52
17.52
4.12
2.51
Net Income
521.48 M
8.04 B
4.87 B
365 M
5.61 B
13.33 B
6.72 B
5.24 B
6.9 B
5.4 B
Earnings Per Share
1.88
-3.58
2.88
4.78
0.09
6.06
7.82
9.31
2.08
1.89
Shares Owned By Insiders
1.18
0.11
0.09
0.06
0.11
0.09
0.21
0.15
N/A
N/A
Revenue
3.63 B
45.01 B
54.32 B
60.12 B
27.12 B
85.16 B
28.19 B
34.12 B
45.81 B
46.03 B
Working Capital
2.7 B
9.51 B
(4.84 B)
6.47 B
4.8 B
7.21 B
11.94 B
(1.57 B)
(5.49 B)
6.46 B
Cash And Equivalents
2.13 B
9.12 B
11.88 B
12.69 B
6.14 B
5.37 B
11.48 B
2.07 B
4.52 B
6.9 B
Cash Per Share
9.4
6.21
6.72
4.44
4.9
13.03
21.51
2.97
1.46
2.76
Gross Profit
2.8 B
36.38 B
41.53 B
42.08 B
21.62 B
63.95 B
19.92 B
21.91 B
35.73 B
31.7 B
Day Typical Price
100.55
58.26
174.74
100.32
91.98
146.44
273.42
793.97
67.45
47.95
Accumulation Distribution
0.0127
0.0177
116489.0
0.0085
0.0249
N/A
92675.88
57646.3
58602.41
14349.82
Market Facilitation Index
1.29
1.04
N/A
0.86
2.31
N/A
0.0
0.0
N/A
N/A
Daily Balance Of Power
0.1008
(0.57)
(0.60)
1.0
0.7576
(9,223,372,036,855)
(0.41)
(0.27)
0.4074
(0.24)
Period Momentum Indicator
0.13
(0.59)
(1.30)
0.86
1.75
(0.20)
(2.34)
(3.55)
0.22
(0.09)
Rate Of Daily Change
1.0
0.99
0.99
1.01
1.02
1.0
0.99
1.0
1.0
1.0
Day Median Price
100.63
58.33
174.92
100.18
91.8
146.44
273.43
792.94
67.47
47.94
Price Action Indicator
(0.16)
(0.51)
(1.20)
0.86
1.42
(0.10)
(1.19)
1.32
0.04
0.01
Coefficient Of Variation
(1,338)
632.6
(1,202)
(598.51)
571.93
(420.40)
(651.36)
(1,117)
(547.25)
(396.24)
Mean Deviation
0.7077
1.3
1.01
0.9334
0.9965
0.6026
1.08
1.32
1.06
0.819
Jensen Alpha
(0.22)
0.3314
(0.19)
(0.24)
0.2268
(0.22)
(0.37)
(0.22)
(0.26)
(0.30)
Total Risk Alpha
(0.46)
(0.01)
(0.50)
(0.40)
0.0142
(0.32)
(0.53)
(0.48)
(0.51)
(0.47)
Sortino Ratio
N/A
0.1288
N/A
N/A
0.0882
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
2.07
N/A
N/A
2.29
N/A
N/A
N/A
N/A
N/A
Standard Deviation
1.92
1.96
2.03
1.21
1.48
0.7785
1.65
1.88
1.48
1.12
Kurtosis
45.05
11.0
22.27
(0.20)
5.59
(0.05)
5.59
1.78
6.56
4.26
Potential Upside
1.13
2.23
2.3
2.0
2.17
1.4
1.85
2.71
1.32
1.13
Treynor Ratio
(0.27)
(1.09)
(1.46)
(0.80)
1.33
(0.94)
(0.29)
(0.47)
1.75
(6.63)
Maximum Drawdown
16.07
14.39
18.93
5.18
10.8
3.25
9.43
9.21
8.5
7.81
Variance
3.7
3.84
4.14
1.47
2.18
0.606
2.73
3.52
2.18
1.26
Market Risk Adjusted Performance
(0.26)
(1.08)
(1.45)
(0.79)
1.34
(0.93)
(0.28)
(0.46)
1.76
(6.62)
Risk Adjusted Performance
(0.05)
0.1205
(0.05)
(0.12)
0.1314
(0.17)
(0.11)
(0.06)
(0.13)
(0.18)
Skewness
(5.92)
2.28
(3.01)
0.1516
0.8632
(0)
(1.87)
(0.43)
(1.89)
0.569
Semi Deviation
N/A
1.2
N/A
N/A
1.14
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.14)
0.0946
(0.14)
(0.27)
0.0905
(0.40)
(0.23)
(0.16)
(0.27)
(0.36)
Value At Risk
(0.87)
(2.07)
(2.39)
(2.17)
(1.82)
(1.55)
(4.16)
(3.47)
(2.78)
(1.85)
Expected Short fall
N/A
(1.49)
N/A
N/A
(0.99)
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
1.44
N/A
N/A
1.51
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
1.44
N/A
N/A
1.29
N/A
N/A
N/A
N/A
N/A

Horizon Pharma Competition Performance Charts

Five steps to successful analysis of Horizon Pharma Competition

Horizon Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Horizon Pharma PLC in relation to its competition. Horizon Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Horizon Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Horizon Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Horizon Pharma PLC, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Horizon Pharma position

In addition to having Horizon Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Furniture Thematic Idea Now

Furniture
Furniture Theme
Companies producing and selling home and office furniture. The Furniture theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in Horizon Stock

If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY